Moderna ‘comfortable’ with guidance for $6B-$8B in FY23 COVID-19 vaccine sales

After Pfizer (PFE) announced that it now anticipates full-year 2023 revenues to be in the range of $58B-$61B, versus its previous guidance range of $67B-$70B “solely due to its COVID products,” Moderna (MRNA) issued the following statement on anticipated 2023 COVID-19 sales: “Moderna remains comfortable that its guided wide range of $6B to $8B for anticipated revenues from sale of its COVID-19 vaccine for the full year 2023, as provided in its second quarter earnings release dated August 3, 2023, reflects the uncertainty of U.S. vaccination rates. As noted previously, if the U.S. market for COVID-19 vaccines is approximately 50 million administered doses, Moderna still expects to be in the bottom half of the disclosed range; if the U.S. market is approximately 100 million administered doses, Moderna still expects to be in the top half of the disclosed range. Moderna believes it is still too early in the U.S. vaccination season to accurately project where vaccination rates will land for the full year. Moderna anticipates that it will have improved visibility about the expected U.S. market size after seeing full vaccination trends through October 2023. Moderna will provide an update at its earnings call on November 2, 2023.”